Gemcitabine for the treatment of ovarian cancer
Dear OncoLink "Ask The Experts,"
Have you or any of your colleagues used Gemzar in the treatment of ovarian cancer? I would like to know of any stats on the success of this chemotherapy for ovarian cancer.
Christina S. Chu, MD, Assistant Professor of the Division of Gynecologic Oncology at the University of Pennsylvania Health System, responds:
Gemcitabine (brand name Gemzar®) is generally used as a second-line treatment for recurrent or persistent ovarian cancer. In general, the rate of response to this chemotherapy is about 15-20%. This means that 15-20% of patients with recurrent or persistent disease will have shrinkage of their tumor after treatment with gemcitabine.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2016 Trustees of The University of Pennsylvania